Patents by Inventor Chi-Ming Liang
Chi-Ming Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348566Abstract: Re-folded human serum albumin (rfHSA) and use thereof for anti-tumor are disclosed. The rfHSA comprises the primary amino acid sequence of naive human serum albumin, in which the rfHSA in a solution is oval shape, not fibrillar, and the naive HSA is globular. The rfHSA is used for treating cancer or a tumor in a subject in need thereof The rfHSA may also be used as a reagent for detecting the presence of a cancer cell associated with integrin ?1 or serine/threonine protein kinase Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) in a tumor sample or as a reagent for inhibiting phosphorylation of Akt and ERK 1/2 in a cancer cell sample. A cell lysate of a cancer cell treated with rfHSA, a vaccine composition comprising the cancer cell lysate, and use thereof are also disclosed. Also disclosed is a method tor preparing rfHSA.Type: ApplicationFiled: September 10, 2021Publication date: November 2, 2023Inventors: Chi-Ming LIANG, Jeng-Jer SHIEH, Chung-Hsuan CHEN, Shu-Mei LIANG
-
Patent number: 9764005Abstract: Methods of using fibrillar proteins are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis.Type: GrantFiled: August 26, 2015Date of Patent: September 19, 2017Assignee: Academia SinicaInventors: Shu-Mei Liang, Ching-Feng Chiu, Shao-Wen Hung, Jei-Ming Peng, Chi-Ming Liang
-
Publication number: 20160051634Abstract: Methods of using fibrillar proteins are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis.Type: ApplicationFiled: August 26, 2015Publication date: February 25, 2016Inventors: Shu-Mei Liang, Ching-Feng Chiu, Shao-Wen Hung, Jei-Ming Peng, Chi-Ming Liang
-
Patent number: 9226951Abstract: Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer.Type: GrantFiled: January 10, 2013Date of Patent: January 5, 2016Assignee: ACADEMIA SINICAInventors: Shu-Mei Liang, Chi-Ming Liang
-
Patent number: 8685923Abstract: A method for inhibiting survival of cancer cells in a subject is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of fibrillar albumin. The preparation of the fibrillar albumin comprises: (i) forming a solution comprising an isolated and/or purified globular albumin; (ii) adding a detergent to the solution containing the isolated and/or purified globular albumin, wherein the detergent is one selected from the group consisting of sodium dodecyl sulfate (SDS) and n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate; (iii) applying the solution to a molecular sizing column with a pore size that permits separation of a protein with a molecular weight of at least about 70 kDa so as to promote column-induced formation of the fibrillar albumin from the isolated and/or purified globular albumin; and (iv) eluting the fibrillar albumin from the column, wherein the eluted albumin has a fibrillar structure.Type: GrantFiled: August 12, 2012Date of Patent: April 1, 2014Assignee: Academia SinicaInventors: Shu-Mei Liang, Chun-Yung Huang, Chi-Ming Liang
-
Patent number: 8357652Abstract: Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer.Type: GrantFiled: November 20, 2009Date of Patent: January 22, 2013Assignee: Academia SinicaInventors: Shu-Mei Liang, Chi-Ming Liang
-
Publication number: 20120316117Abstract: A method for inhibiting survival of cancer cells in a subject is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of fibrillar albumin. The preparation of the fibrillar albumin comprises: (i) forming a solution comprising an isolated and/or purified globular albumin; (ii) adding a detergent to the solution containing the isolated and/or purified globular albumin, wherein the detergent is one selected from the group consisting of sodium dodecyl sulfate (SDS) and n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate; (iii) applying the solution to a molecular sizing column with a pore size that permits separation of a protein with a molecular weight of at least about 70 kDa so as to promote column-induced formation of the fibrillar albumin from the isolated and/or purified globular albumin; and (iv) eluting the fibrillar albumin from the column, wherein the eluted albumin has a fibrillar structure.Type: ApplicationFiled: August 12, 2012Publication date: December 13, 2012Applicant: Academia SinicaInventors: Shu-Mei Liang, Chun-Yung Huang, Chi-Ming Liang
-
Publication number: 20120309682Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.Type: ApplicationFiled: November 19, 2010Publication date: December 6, 2012Inventors: Shu-Mei Liang, Ching-Feng Chiu, Shao-Wen Hung, Jei-Ming Peng, Chi-Ming Liang
-
Patent number: 8268974Abstract: A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, applying the solution to a molecular sizing column with a pore size of at least 70 kDa and eluting with a solution containing detergent. A method for changing an unfolded protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a urea to the solution to unfold the globular protein, applying the solution to a molecular sizing column and eluting with a solution containing detergent. A method for treating cancer comprising the steps of providing a protein, changing the protein into a fibrillar structure, and administering a therapeutically effective amount of the fibrillar structure protein to a patient in need thereof.Type: GrantFiled: April 11, 2008Date of Patent: September 18, 2012Assignee: Academia SinicaInventors: Shu-Mei Liang, Chun-Yung Huang, Yen-Po Chen, Chi-Ming Liang
-
Patent number: 7700730Abstract: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.Type: GrantFiled: December 3, 2007Date of Patent: April 20, 2010Assignee: Academia SinicaInventors: Shu-Mei Liang, Jei-Ming Peng, Chi-Ming Liang
-
Patent number: 7488800Abstract: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.Type: GrantFiled: November 30, 2007Date of Patent: February 10, 2009Assignee: Academia SinicaInventors: Shu-Mei Liang, Jei-Ming Peng, Chi-Ming Liang
-
Publication number: 20080300186Abstract: A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, applying the solution to a molecular sizing column with a pore size of at least 70 kDa and eluting with a solution containing detergent. A method for changing an unfolded protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a urea to the solution to unfold the globular protein, applying the solution to a molecular sizing column and eluting with a solution containing detergent. A method for treating cancer comprising the steps of providing a protein, changing the protein into a fibrillar structure, and administering a therapeutically effective amount of the fibrillar structure protein to a patient in need thereof.Type: ApplicationFiled: April 11, 2008Publication date: December 4, 2008Inventors: Shu-Mei Liang, Chun-Yung Huang, Yen-Po Chen, Chi-Ming Liang
-
Publication number: 20080188410Abstract: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.Type: ApplicationFiled: November 30, 2007Publication date: August 7, 2008Applicant: Academia SinicaInventors: Shu-Mei Liang, Jei-ming Peng, Chi-Ming Liang
-
Publication number: 20080152666Abstract: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.Type: ApplicationFiled: December 3, 2007Publication date: June 26, 2008Applicant: Academia SinicaInventors: Shu-Mei Liang, Jei-Ming Peng, Chi-Ming Liang
-
Patent number: 7323546Abstract: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.Type: GrantFiled: June 8, 2004Date of Patent: January 29, 2008Assignee: Academia SinicaInventors: Shu-Mei Liang, Jei-Ming Peng, Chi-Ming Liang
-
Publication number: 20050058654Abstract: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.Type: ApplicationFiled: June 8, 2004Publication date: March 17, 2005Applicant: Academia SinicaInventors: Shu-Mei Liang, Jei-Ming Peng, Chi-Ming Liang
-
Patent number: 6221620Abstract: The present invention relates to monoclonal antibodies that are specific for the protein thymidylate synthase, and hybridomas producing these monoclonal antibodies. The invention further relates to methods of detection and diagnostic kits to test for the presence of thymidylate synthase. The invention also relates to the use of the monoclonal antibodies in determining the presence of colon carcinoma cells.Type: GrantFiled: April 24, 1991Date of Patent: April 24, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Patrick G. Johnston, Carmen J. Allegra, Bruce A. Chabner, Chi-Ming Liang
-
Patent number: 5866570Abstract: A method for identifying patients at risk of developing vascular leakage syndrome and systemic inflammatory response syndrome (SIRS) such as septic shock by determining the serum levels of metalloproteinase expression, in particular type IV collagenase expression, as well as a method of treating or preventing vascular leakage syndrome and SIRS by the administration of one or more metalloproteinase inhibitors, preferably type IV collagenase inhibitors is taught. Additionally, the therapeutic efficacy of bis(dioxopiperazine) compounds is determined on the basis of collagenase inhibiting activity, and the compounds which inhibit collagenase activity are utilized for the treatment of collagenase related disorders, e.g., vascular leakage syndrome, septic shock, stroke, cardiac disorders, angiogenesis, and arthritis.Type: GrantFiled: June 21, 1994Date of Patent: February 2, 1999Assignee: Wisconsin Alumni Research FoundationInventors: Chi-Ming Liang, Nancy A. Turner, Donald T. Witiak